Cross-reactive antibodies elicited to conserved epitopes on SARS-CoV-2 spike protein after infection and vaccination.

Autor: Geanes ES; Genomic Medicine Center, Children's Mercy Research Institute, Kansas City, MO, USA., LeMaster C; Genomic Medicine Center, Children's Mercy Research Institute, Kansas City, MO, USA., Fraley ER; Genomic Medicine Center, Children's Mercy Research Institute, Kansas City, MO, USA., Khanal S; Genomic Medicine Center, Children's Mercy Research Institute, Kansas City, MO, USA., McLennan R; Genomic Medicine Center, Children's Mercy Research Institute, Kansas City, MO, USA., Grundberg E; Genomic Medicine Center, Children's Mercy Research Institute, Kansas City, MO, USA.; Department of Pediatrics, University of Missouri- Kansas City, Kansas City, MO, USA.; Department of Pediatrics, University of Kansas Medical Center, Kansas City, MO, USA.; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA., Selvarangan R; Department of Pediatrics, University of Missouri- Kansas City, Kansas City, MO, USA.; Department of Pathology and Laboratory Medicine, Children's Mercy, Kansas City, MO, USA., Bradley T; Genomic Medicine Center, Children's Mercy Research Institute, Kansas City, MO, USA. tcbradley@cmh.edu.; Department of Pediatrics, University of Missouri- Kansas City, Kansas City, MO, USA. tcbradley@cmh.edu.; Department of Pediatrics, University of Kansas Medical Center, Kansas City, MO, USA. tcbradley@cmh.edu.; Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA. tcbradley@cmh.edu.
Jazyk: angličtina
Zdroj: Scientific reports [Sci Rep] 2022 Apr 20; Vol. 12 (1), pp. 6496. Date of Electronic Publication: 2022 Apr 20.
DOI: 10.1038/s41598-022-10230-y
Abstrakt: SARS-CoV-2 is a novel betacoronavirus that caused coronavirus disease 2019 and has resulted in millions of deaths worldwide. Novel coronavirus infections in humans have steadily become more common. Understanding antibody responses to SARS-CoV-2, and identifying conserved, cross-reactive epitopes among coronavirus strains could inform the design of vaccines and therapeutics with broad application. Here, we determined that individuals with previous SARS-CoV-2 infection or vaccinated with the Pfizer-BioNTech BNT162b2 vaccine produced antibody responses that cross-reacted with related betacoronaviruses. Moreover, we designed a peptide-conjugate vaccine with a conserved SARS-CoV-2 S2 spike epitope, immunized mice and determined cross-reactive antibody binding to SARS-CoV-2 and other related coronaviruses. This conserved spike epitope also shared sequence homology to proteins in commensal gut microbiota and could prime immune responses in humans. Thus, SARS-CoV-2 conserved epitopes elicit cross-reactive immune responses to both related coronaviruses and host bacteria that could serve as future targets for broad coronavirus therapeutics and vaccines.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje